Seeking Biomarkers for Acute Graft-versus-host Disease: Where We Are and Where We Are Heading?

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2019 Aug 14

PMID 31406575

Citations 11

Authors

Xiao-Su Zhao

Xiao-Jun Huang

Affiliations

Soon will be listed here.

Abstract

Acute graft-versus-host disease (aGVHD) is one of the most important complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which would seriously affect the clinical outcomes of patients. Early diagnosis and early intervention are keys for improving its curative efficacy. Thus, seeking the biomarkers of aGVHD that can accurately identify and diagnose aGVHD is very important to guiding the intervention and treatment of aGVHD. For the past decades, many studies have focused on searching for aGVHD-related biological markers to assist in diagnosis, early warning, and risk stratification. Unfortunately, until now, no reliable aGVHD biomarker is available that is recognized and widely used in clinical practice. With the continuous development of biological technology, as well as our in-depth understanding of the pathophysiologic mechanism of aGVHD, the selection, examination and application of biological markers have changed much. In this review, we summarized the progress of aGVHD biological marker screening, identification, preliminary clinical application, and look forward to a promising development direction in the future.

Citing Articles

Gut microbiota plays pivotal roles in benign and malignant hematopoiesis.

Li Y, Zhang B, Jiang L, Cheng T, Cheng H, Qian P Blood Sci. 2024; 6(4):e00200.

PMID: 39027904 PMC: 11257671. DOI: 10.1097/BS9.0000000000000200.

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation.

Rowley S, Gunning T, Pelliccia M, Della Pia A, Lee A, Behrmann J Cancers (Basel). 2024; 16(7).

PMID: 38611035 PMC: 11011125. DOI: 10.3390/cancers16071357.

Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?.

Alexoudi V, Gavriilaki E, Cheva A, Sakellari I, Papadopoulou S, Paraskevopoulos K Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543084 PMC: 10975293. DOI: 10.3390/ph17030298.

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.

Tang L, Huang Z, Mei H, Hu Y Signal Transduct Target Ther. 2023; 8(1):306.

PMID: 37591844 PMC: 10435569. DOI: 10.1038/s41392-023-01521-5.

Pre-Transplant Prediction of Acute Graft-versus-Host Disease Using the Gut Microbiome.

Zargari Marandi R, Jorgensen M, Ilett E, Norgaard J, Noguera-Julian M, Paredes R Cells. 2022; 11(24).

PMID: 36552852 PMC: 9776596. DOI: 10.3390/cells11244089.

References

Pfundt R, Wingens M, Bergers M, Zweers M, Frenken M, Schalkwijk J . TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res. 2000; 292(4):180-7. DOI: 10.1007/s004030050475. View

Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K . Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol. 2000; 109(3):652-7. DOI: 10.1046/j.1365-2141.2000.02095.x. View

Mathias C, Mick R, Grupp S, Duffy K, Harris F, Laport G . Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. J Hematother Stem Cell Res. 2000; 9(3):393-400. DOI: 10.1089/15258160050079506. View

Huang X, Wan J, Lu D . Serum TNFalpha levels in patients with acute graft-versus-host disease after bone marrow transplantation. Leukemia. 2001; 15(7):1089-91. DOI: 10.1038/sj.leu.2402151. View

Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T, Kakishita E . Increased hepatocyte growth factor in serum in acute graft-versus-host disease. Bone Marrow Transplant. 2001; 28(2):197-200. DOI: 10.1038/sj.bmt.1703095. View

Nieuw Amerongen A, Veerman E . Saliva--the defender of the oral cavity. Oral Dis. 2002; 8(1):12-22. DOI: 10.1034/j.1601-0825.2002.1o816.x. View

Viale M, Ferrini S, Bacigalupo A . TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1992; 10(3):249-53. View

Eklund C, Lehtimaki T, Hurme M . Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin-1B SNP +3954 on CRP concentration in healthy male blood donors. Int J Immunogenet. 2005; 32(4):229-32. DOI: 10.1111/j.1744-313X.2005.00515.x. View

Weston L, Geczy A, Briscoe H . Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD. Bone Marrow Transplant. 2005; 37(2):207-12. DOI: 10.1038/sj.bmt.1705218. View

10.

Ferrara J, Reddy P . Pathophysiology of graft-versus-host disease. Semin Hematol. 2006; 43(1):3-10. DOI: 10.1053/j.seminhematol.2005.09.001. View

11.

Shaiegan M, Iravani M, Babaee G, Ghavamzadeh A . Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol. 2006; 15(3):223-7. DOI: 10.1016/j.trim.2005.10.002. View

12.

Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani B, Zeilah J . High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006; 108(4):1291-7. PMC: 1895877. DOI: 10.1182/blood-2006-02-003996. View

13.

Pabst C, Schirutschke H, Ehninger G, Bornhauser M, Platzbecker U . The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res. 2007; 13(10):2916-22. DOI: 10.1158/1078-0432.CCR-06-2602. View

14.

Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U . Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood. 2007; 110(13):4535-42. DOI: 10.1182/blood-2006-10-049817. View

15.

Elmaagacli A, Koldehoff M, Landt O, Beelen D . Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant. 2008; 41(9):821-6. DOI: 10.1038/sj.bmt.1705980. View

16.

Choi S, Kitko C, Braun T, Paczesny S, Yanik G, Mineishi S . Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008; 112(4):1539-42. PMC: 2515125. DOI: 10.1182/blood-2008-02-138867. View

17.

Luo X, Chang Y, Xu L, Liu D, Liu K, Huang X . The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant. 2008; 43(1):29-36. DOI: 10.1038/bmt.2008.267. View

18.

Paczesny S, Krijanovski O, Braun T, Choi S, Clouthier S, Kuick R . A biomarker panel for acute graft-versus-host disease. Blood. 2008; 113(2):273-8. PMC: 2615645. DOI: 10.1182/blood-2008-07-167098. View

19.

Dickinson A . Non-HLA genetics and predicting outcome in HSCT. Int J Immunogenet. 2008; 35(4-5):375-80. DOI: 10.1111/j.1744-313X.2008.00790.x. View

20.

Han Y, Guo Q, Zhang M, Chen Z, Cao X . CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol. 2008; 182(1):111-20. DOI: 10.4049/jimmunol.182.1.111. View